Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07527650 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT07527650 is a Phase 2 study that is actively recruiting participants, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 180 participants.
The verdict
NCT07527650, a Phase 2 study, is actively recruiting participants, sponsored by Hanmi Pharmaceutical Company Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
Interventions
- DRUG HM15275
- DRUG Placebo of HM15275
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07527650
The ClinicalTrials.gov registry entry for NCT07527650 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HM15275 is the first listed.
NCT07527650 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07527650 about?
NCT07527650 is a clinical study titled "Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus". This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
What is the current status of trial NCT07527650?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2026-05-18. Estimated completion is 2027-10.
What interventions are being tested in trial NCT07527650?
The interventions under investigation include: HM15275 (DRUG), Placebo of HM15275 (DRUG).
Who is sponsoring clinical trial NCT07527650?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.